Toxicity (≥ G3) · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
1 finding from 1 review
RR 1.69 [1.19, 2.42]
1142 participants
Moderate
Toxicity (≥ G3) · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies with showed no clear difference in toxicity (≥ G3) compared with without anti‐PD1 monoclonal antibodies (low certainty).
1 finding from 1 review
RR 1.57 [0.85, 2.92]
764 participants
Low
Toxicity (≥ G3) · people with cutaneous melanoma
BRAF inhibitors showed no clear difference in toxicity (≥ G3) compared with chemotherapy (low certainty).
1 finding from 1 review
RR 1.27 [0.48, 3.33]
408 participants
Low
Toxicity (≥ G3) · people with cutaneous melanoma
MEK inhibitors probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
1 finding from 1 review
RR 1.61 [1.08, 2.41]
91 participants
Moderate
Toxicity (≥ G3) · people with cutaneous melanoma
BRAF plus MEK inhibitors showed no clear difference in toxicity (≥ G3) compared with BRAF inhibitors (moderate certainty).
1 finding from 1 review
RR 1.01 [0.85, 1.2]
1774 participants
Moderate
Toxicity (≥ G3) · people with cutaneous melanoma
Anti‐angiogenic drugs plus chemotherapy showed no clear difference in toxicity (≥ G3) compared with chemotherapy (low certainty).
1 finding from 1 review
RR 0.68 [0.09, 5.32]
324 participants
Low
Toxicity (≥ G3) · people with cutaneous melanoma
Biochemotherapy leads to higher toxicity (≥ G3) compared with chemotherapy (high certainty).
1 finding from 1 review
RR 1.35 [1.14, 1.61]
631 participants
High
Toxicity (≥ G3) · people with cutaneous melanoma
1 finding from 1 review
0.55 [0.31, 0.97]
1360 participants
Low
Toxicity (≥ G3) · people with cutaneous melanoma
Polychemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
1 finding from 1 review
RR 1.97 [1.44, 2.71]
390 participants
Moderate
Toxicity (≥ G3) · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies may leads to lower toxicity (≥ G3) compared with anti‐CTLA4 monoclonal antibodies (low certainty).
1 finding from 1 review
RR 0.7 [0.54, 0.91]
1465 participants
Low